CN111467466A

CN111467466A - New application of radix bupleuri granule in preventing and treating syncytial virus and adenovirus

Info

Publication number: CN111467466A
Application number: CN202010403390.2A
Authority: CN
Inventors: 刘宏; 黄伟; 陈祥云; 毕聪; 郑如文; 江志强; 张俊华; 何逸禧; 杜海泳
Original assignee: Guangzhou Baiyunshan Guanghua Pharmacy Co ltd
Current assignee: Guangzhou Baiyunshan Guanghua Pharmacy Co ltd
Priority date: 2020-05-13
Filing date: 2020-05-13
Publication date: 2020-07-31

Abstract

The invention relates to application of bupleurum particles in preparing a medicament for preventing and treating diseases caused by respiratory tract virus infection, which finds that the bupleurum particles have good in-vitro antiviral (syncytial virus and adenovirus) activity, can improve lung injury caused by the syncytial virus and the adenovirus, obviously relieves respiratory peroxidation injury caused by the virus, obviously increases the free radical scavenging capacity of organisms (obviously regulates and controls CAT, SOD, GSH-px, MDA, NO, MPO, TNF-a, I L-6, ROS, superoxide anion resistance and the like), and presents dose-effect relationship characteristics, namely finds a new effect of the bupleurum particles in inhibiting the syncytial virus, the adenovirus and free radical injury caused by the syncytial virus and the adenovirus.

Description

New application of radix bupleuri granule in preventing and treating syncytial virus and adenovirus

Technical Field

The present invention belongs to the field of Chinese patent medicine, and relates to a new application of Chinese medicine composition-Xiaochaihu granules in preventing and curing syncytial virus and adenovirus.

Background

The main symptoms of respiratory tract infection are fever, cough, nasal obstruction and the like, the disease is mainly caused by bacterial and viral infection, wherein the proportion of the viral infection is up to more than 90 percent, and the viruses are especially common as syncytial virus and adenovirus. Respiratory syncytial virus is an RNA virus belonging to the family of paramyxoviridae. In the last decade, the syncytial virus pneumonia and the bronchiolitis account for the first viral pneumonia of infants in China, and the symptoms of the pneumonia and the pneumonia of parainfluenza virus, mild influenza virus and mild adenovirus can hardly be distinguished clinically. Adenovirus (adenovirus) is a particle without an envelope and with the diameter of 70-90 nm, and consists of 252 capsomeres arranged in a icosahedron shape. The diameter of each shell particle is 7-9 nm. Inside the capsid is a linear double-stranded DNA molecule of about 4.7kb with inverted repeats of about 100bp each at both ends. There are 52 known human adenoviruses, named adl-ad 52, which were most studied ad2 and were divided into A, B, C, D, E and six subgroups (subgroups). Adenoviruses are infectious to the respiratory, gastrointestinal, urinary and bladder, eye, liver, etc., and the known serotypes of human adenoviruses of about 1/3 are commonly associated with human disease, but one serotype can cause different clinical conditions; conversely, different serotypes may cause the same disease. Adenovirus pneumonia accounts for about 10% of pneumonia in childhood, and is mostly caused by adenovirus type 3 and 7; the fatality rate of adenovirus pneumonia in young people is 8% -10%; pneumonia is also a serious manifestation of acute respiratory diseases of new soldiers. Upper respiratory infection caused by respiratory syncytial virus and adenovirus has the characteristics of acute morbidity, rapid transmission and the like, and if the upper respiratory infection cannot be effectively controlled in time, capillary bronchitis, bronchopneumonia and the like can be caused, so that the life and the health are seriously threatened. Epidemiological investigations have shown that Respiratory Syncytial Virus (RSV) infection and adenovirus infection occur well in infants and are one of the leading causes of infant mortality. Ribavirin is a traditional antiviral drug, is commonly used clinically in the treatment of various viral infectious diseases, but has limited efficacy and risks of bone marrow and immunosuppression in long-term use. Therefore, the development of new medicaments for inhibiting respiratory tract infection caused by the syncytial virus and the adenovirus has important practical significance and social significance.

Free radicals are intermediate metabolites of various biochemical reactions in human life activities, and have molecules, atoms, ions or atomic groups with unpaired electrons, and in order to stabilize themselves, free radicals can actively capture electrons of other atoms or molecules. If the balance between the generation and the elimination of free radicals is broken, the free radicals can attack biomacromolecules and various organelles in the organism, and the organism is damaged. The virus invader induces a large amount of oxygen radicals, such as: superoxide anion radicals, hydrogen peroxide, hydroxyl radicals, singlet oxygen, and the like. Meanwhile, the virus can activate macrophages to generate excessive nitric oxide to react to generate peroxynitrite. The two cause the increase of the oxidative stress level, the local injury of the organism, the reduction of the whole immune response function and the lipid peroxidation injury of the biomembrane, and finally the lung tissue injury. After the virus infects the body, free radicals are the main cause of body damage. Therefore, the removal of excessive free radicals caused by viruses is of great significance to the protection of organisms and the treatment of virus infection.

The bupleurum tenue granule is a pure Chinese medicinal preparation developed according to the minor bupleurum tenue soup in the classic famous prescription of the Shanghai medical science of Shengzhang Zhongjing treatise on the exogenous febrile diseases, is a main prescription for treating cold, influenza, various variant influenza and other exogenous febrile diseases, and is a granular Chinese patent medicine preparation prepared by seven medicinal ingredients of bupleurum, scutellaria, pinellia (processed by ginger), codonopsis pilosula, ginger, liquorice and Chinese date according to the prescription of monarch, minister, assistant and guide. The bupleurum tenue particles have the effects of relieving exterior syndrome and dispersing stagnated liver qi and harmonizing stomach, can effectively improve the resistance and immunity of human bodies, and have obvious prevention and control curative effects on cold, flu and the like. At present, the application of bupleurum tenue particles in inhibiting syncytial virus, adenovirus and free radical damage caused by the syncytial virus and the adenovirus is not related.

Disclosure of Invention

One of the purposes of the invention is to provide a new clinical application of a traditional Chinese medicine composition, namely Xiaochaihu granules.

The technical scheme for achieving the aim comprises the following steps.

The application of a traditional Chinese medicine composition in preparing a medicine for preventing and treating diseases caused by respiratory virus infection comprises the following active components in parts by weight: 150 +/-5 parts of radix bupleuri, 56 +/-5 parts of scutellaria baicalensis, 56 +/-3 parts of ginger processed pinellia, 56 +/-3 parts of codonopsis pilosula, 56 +/-3 parts of ginger, 56 +/-3 parts of liquorice and 56 +/-3 parts of Chinese dates, wherein the respiratory viruses are syncytial viruses and/or adenoviruses.

The application of a traditional Chinese medicine composition in preparing a medicine for eliminating excessive free radicals caused by respiratory virus infection comprises the following active ingredients in parts by weight: 150 +/-5 parts of radix bupleuri, 56 +/-5 parts of scutellaria baicalensis, 56 +/-3 parts of ginger processed pinellia, 56 +/-3 parts of codonopsis pilosula, 56 +/-3 parts of ginger, 56 +/-3 parts of liquorice and 56 +/-3 parts of Chinese dates, wherein the respiratory viruses are syncytial viruses and/or adenoviruses.

In some of these embodiments, the respiratory virus is a syncytial virus and an adenovirus.

In some embodiments, the respiratory virus is an adenovirus, and in some preferred embodiments, the adenovirus is ADV3, ADV4, ADV5, ADV6, ADV7, ADV11, ADV21, and more preferably, ADV 3.

In some of these embodiments, the disease is pneumonia.

In some embodiments, the active ingredients of the traditional Chinese medicine composition comprise the following components in parts by weight: 150 parts of radix bupleuri, 56 parts of scutellaria baicalensis, 56 parts of ginger processed pinellia, 56 parts of codonopsis pilosula, 56 parts of ginger, 56 parts of liquorice and 56 parts of Chinese dates.

In some preferred embodiments, the dosage form of the Chinese medicinal composition is granules.

According to the invention, an in vitro antiviral experiment and an in vivo mouse virus infection model experiment are adopted, and a syncytial virus and an adenovirus are taken as infectious viruses for experiment, so that the bupleurum tenue particles have good in vitro antiviral (syncytial virus and adenovirus) activity, lung injury caused by the syncytial virus and the adenovirus can be improved, respiratory peroxidation injury caused by the virus is obviously relieved, the free radical scavenging capacity of an organism is obviously increased (CAT, SOD, GSH-px, MDA, NO, MPO, TNF-a, I L-6, ROS, superoxide anion resistance and the like are obviously regulated and controlled), and the dose-effect relationship characteristic is presented.

Drawings

FIG. 1, FIG. 2, FIG. 3 and FIG. 4 are graphs showing the effect of each group of drugs on serum TNF-a, I L-6, ROS and anti-superoxide anion of RSV infected mice in example 3 of the present invention;

FIG. 5, FIG. 6, FIG. 7, FIG. 8, FIG. 9 and FIG. 10 are graphs showing the effect of the drugs of each group in example 3 on CAT, SOD, GSH-px, MDA, NO and MPO in RSV-infected mouse lung tissues, respectively;

FIG. 11, FIG. 12, FIG. 13 and FIG. 14 are graphs showing the effect of the drugs of each group on ADV 3-infected mouse serum TNF-a, I L-6, ROS and superoxide anion in example 3 of the present invention;

FIG. 15, FIG. 16, FIG. 17, FIG. 18, FIG. 19 and FIG. 20 are graphs showing the effect of the drugs of each group on ADV 3-infected mouse lung tissues CAT, SOD, GSH-px, MDA, NO and MPO in example 3 of the present invention.

Detailed Description

The following examples of the present invention are experimental methods without specifying specific conditions, generally according to conventional conditions, or according to conditions recommended by the manufacturer. The various chemicals used in the examples are commercially available.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

The terms "comprising" and "having" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, apparatus, product, or device that comprises a list of steps is not limited to only those steps or components listed, but may alternatively include other steps or components not listed, or inherent to such process, method, product, or device.

The "plurality" referred to in the present invention means two or more. "and/or" describes the association relationship of the associated objects, meaning that there may be three relationships, e.g., a and/or B, which may mean: a exists alone, A and B exist simultaneously, and B exists alone. The character "/" generally indicates that the former and latter associated objects are in an "or" relationship.

In order that the invention may be more fully understood, reference will now be made to the following description. The present invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.

The bupleurum tenue granules in the following embodiments are sold by Guangzhou Baiyunshan Guanghua pharmacy, and the active ingredients of the bupleurum tenue granules specifically comprise: 150g of radix bupleuri, 56g of radix scutellariae, 56g of ginger processed pinellia, 56g of radix codonopsitis, 56g of ginger, 56g of liquorice and 56g of Chinese date, and the preparation is granules. Since the adjuvant sucrose can cause false positive results in the antibacterial test, this study used bupleurum tenue granules (sugarless version) for the subsequent tests.

Example 1

Example 1: in vitro antiviral inhibition test of Xiaochaihu granules

1. Experimental materials:

1.1 test drugs: xiaochaihu granules (sugar-free, Guangzhou Baiyunshan Guanghua pharmaceutical GmbH).

1.2 control drugs: ribavirin.

1.3 viral strains syncytial virus (RSV, &ttttransfer = L "&tttL &ttt/T &tttong strain), adenovirus (ADV3 type, ADV4 type, ADV5 type, ADV6 type, ADV7 type, ADV11 type, ADV21 type), virus with Hela cell monolayer for continuous passage 2 times, cell culture fluid harvested and frozen in a-80 ℃ refrigerator for later use.

1.4 cell model: hep-2 cells.

2. The experimental method comprises the following steps:

2.1 determination of viral virulence

100 μ l of 10-fold serially diluted virus solution with 8 multiple wells per concentration was sequentially inoculated into a 96-well plate full of a monolayer of Hep-2 cell layer, and cell control was also provided. 37 ℃ and 5% CO₂The virus was cultured in an incubator, and cytopathic effect (CPE) was observed day by day with an inverted microscope for 3 days continuously, and detection was carried out by MTT method. The absorbance OD was measured at a wavelength of 570nm in a microplate reader, and the half-infective dose of the virus (TCID50) was calculated by the Reed-Muench method.

And (3) measuring results: RSV has a viral virulence TCID50 of 10 in Hep-2 cells^-6.10.1m L, adenovirus (ADV3 type, ADV4 type, ADV5 type, ADV6 type, ADV7 type, ADV11 type, ADV21 type) has 10 virus virulence TCID50 in Hep-2 cells respectively^-5.3/0.1mL、10^-5.7/0.1mL、10^-5.0/0.1mL、10^-5.3/0.1mL、10^-4.9/0.1mL、10^-5.0/0.1mL、10^-5.4/0.1mL。

2.2 measurement of cytotoxicity of Xiaochaihu granules

Collecting 96-well cell culture plate with Hep-2 cells grown into monolayer, decanting the culture solution, washing with PBS for 2 times, adding serum-free DMEM culture medium, serially diluting (1600 μ g/m L-50 μ g/m L) bupleuri radix granule liquid medicine with concentration of 100 μ l/well, setting 4 multiple wells for each concentration, setting 4 normal cell control wells at 37 deg.C and 5% CO₂Culturing in virus incubator for 72h, detecting by MTT method, and measuring absorbance of each experimental group and cell control group at 570nm wavelength. The viability ratio of the cells in each test well was calculated with reference to the control well. Cell TC50 was calculated according to the Reed-Muench method, and the whole experiment was repeated 3 times and averaged.

The result of the measurement is that the cell half toxicity TC50 of the bupleurum tenue granules is more than 770 mug/m L.

2.3 antiviral Activity test of Xiaochaihu granules

A96-well cell culture plate in which Hep-2 cells had grown in a monolayer was removed by decantation, and washed with PBS 2Then, 100. mu.l/well of 100TCID50 virus solution was added thereto at 37 ℃ with 5% CO₂Adsorbing for 2h, adding serial 2 times diluted (200 μ g/m L-12.5 μ g/m L) bupleuri radix granule liquid medicine in DMEM medium without serum, and setting virus control group, cell control group, and positive medicine group at 37 deg.C with 5% CO₂The inhibition rate of the drug to the virus is calculated according to the following formula, wherein the (%) inhibition rate of the drug to the virus is × 100% (drug treatment group OD mean value-virus control group OD mean value)/(cell control group OD mean value-virus control group OD mean value), the inhibition rate of the drug to the CPE caused by RSV or adenovirus (ADV3 type, ADV4 type, ADV5 type, ADV6 type, ADV7 type, ADV11 type and ADV21 type), the EC50 and the drug toxicity-inhibiting index (TI) are calculated according to the Reed-Muench method, and the whole experiment is repeated for 3 times to take the mean value.

According to the MTT result, the inhibition rates of CPE of the bupleurum tenue particles and ribavirin groups are respectively more than 45% and can obviously inhibit the proliferation of RSV and adenovirus (P is less than 0.01) by adopting a Reed-Muench method, wherein the EC 3 of the bupleurum tenue particles to RSV and adenovirus (ADV3 type, ADV3 type and ADV3 type) is respectively 30.3 mu g/m 3, 29.6 mu g/m 3, 28.6 mu g/m 3, 26.7 mu g/m 3, 29.1 mu g/m 32, 27.3 mu g/m 3, 29.4 mu g/m 3, 32.8 mu g/m 3, TI is respectively 26.78, 26.52, 25.93, 3, 26.27.27.27.72, 29.4 mu g/m 3, 32.8 mu g/m 3, TI is respectively 26.72, 26.52, 25.72, 25.27.72, 25.14 mu g/m 3, 18 g/m 3619.72, ADV 3619 mu g/m 3, ADV 3619, ADV 3614, ADV3, ADV 3619.72, ADV 3619.11, ADV3, ADV 19.72, ADV 3614, ADV 19.72, ADV 19 mu g/m 3, ADV 19, ADV 19.72, ADV3, ADV 19.72, ADV 19.11.72, ADV 19.19.

And (4) conclusion: the safety of the bupleurum tenue granules is better than that of ribavirin, and the bupleurum tenue granules have stronger inhibiting effect on RSV and adenovirus (ADV3 type, ADV4 type, ADV5 type, ADV6 type, ADV7 type, ADV11 type and ADV21 type) in Hep-2 cells, and have antiviral effect.

Example 2: experiment of small bupleurum particles in vivo on mouse pneumonia model infected by syncytial virus and adenovirus

1. Experimental materials:

1.2 control drugs: ribavirin.

1.3 viruses syncytial virus (RSV, &. lTtT transformation = L "&. gTt L &. lTt/T &. gTt ong strain), adenovirus (type ADV 3).

2. Experimental animals: the SPF-level Kunming mice comprise 18-20 g of 120 male mice, and are provided by Guangdong province medical experimental animal center with the qualification number SYXK (Guangdong) 2019-. The experiment is started one week after the experimental animals are adapted to the new environment, and an appropriate method is adopted to reduce the harm to the animals in the experimental process.

3. The experimental method comprises the following steps:

3.1 anti-syncytial virus infection mouse model of pneumonia

Randomly dividing mice into a blank control group, a RSV model group, a ribavirin group, a bupleurum tenue granule low dose group (5.4g/kg, which is a clinical equivalent dose of a human body), a bupleurum tenue granule medium dose group (10.8g/kg) and a bupleurum tenue granule high dose group (21.6g/kg), wherein the total number of the groups is six, 10 mice are per group, the mice are slightly anesthetized by ether, and except the blank control group, each mouse uses 25 mu L50L D₅₀The virus drops are used for nasal infection, and the blank control group is used for nasal dropping with the same amount of physiological saline. 1h after infection, the blank control group and the model group are subjected to intragastric perfusion with equal volume of normal saline, and the low, medium and high dose groups of the small bupleurum particles are subjected to intragastric perfusion with the small bupleurum particle liquid medicine once a day for 5 consecutive days.

3.2 model of pneumonia of mouse infected by ADV3 virus

Randomly dividing mice into a blank control group, an ADV3 model group, a ribavirin group, a small bupleurum particle low dose group (5.4g/kg, which is a clinical equivalent dose of a human body), a small bupleurum particle medium dose group (10.8g/kg) and a small bupleurum particle high dose group (21.6g/kg), wherein six groups are provided, 10 mice are in each group, and each mouse is slightly anesthetized by ether, except the blank control group, the dose of 25 mu L50L D is applied to each mouse₅₀The virus drops are used for nasal infection, and the blank control group is used for nasal dropping with the same amount of physiological saline. 1h after infection, performing equal volume of normal saline intragastric administration on the blank control group and the model group, and performing intragastric administration on the granule liquid medicine of bupleuri radix in the low, medium and high dosage groups of the granule of bupleuri radix once a day, and connectingAnd 5 days continuously, on the 6 th day after infection, the mice are killed by dissection, the mice are fasted without water supply for more than 12 hours before the killing by dissection, the lungs of the mice are taken out after axillary artery bloodletting and killing, the lungs of the mice are placed in a culture dish containing 9 g/L of normal saline, surface blood is cleaned, surface water is sucked by absorbent paper, then the lungs of the mice are placed on tin foil to be weighed together to be wet mass, a prepared mark is placed in a 65 ℃ oven to be dried for 48 hours, the dry mass is weighed after the mass is not changed, and the lung wet-dry ratio, the lung index and the lung index inhibition rate are calculated.

4. And (4) experimental conclusion:

the greater the lung index value to lung wet-dry ratio, the more severe the pneumonia. The results show that (table 1 and table 2), the bupleurum tenue particles can obviously reduce the lung index and the lung wet-dry ratio of mice infected by RSV and ADV3, and respectively present dose-effect characteristics to RSV and ADV3, which shows that the bupleurum tenue particles have an improvement effect on pneumonia caused by syncytial virus and adenovirus.

TABLE 1 Effect of Xiaochaihu granules on pulmonary index and pulmonary Wet-Dry ratio of RSV infected mouse pneumonia model (n ═ 10)

Group of	Index of lung	Dry-wet ratio of lung	Inhibition ratio (%)
				Blank control group	0.75±0.07	2.25±0.23	—
Model set	1.46±0.18##	6.07±0.40##	—
				Ribavirin group	0.83±0.07**	4.70±0.24**	43.15
Low dose test group	1.27±0.15*	4.76±0.12**	13.01
				Middle dose test group	0.98±0.08**	4.62±0.15**	32.88
High dose test group	0.93±0.04**	4.45±0.13**	37.58

Note: compared with the blank control group, # P <0.05, # P < 0.01; p <0.05 compared to model control,

**P<0.01

TABLE 2 Effect of Xiaochaihu granules on lung index and lung wet-dry ratio of ADV 3-infected mouse model pneumonia (n ═ 10)

**P<0.01

example 3: experiment for removing excess free radicals in mice pneumonia model infected by syncytial virus and adenovirus by using bupleurum tenue particles

1. Experimental materials:

1.2 control drugs: ribavirin.

1.4. Experimental animals: the SPF-level Kunming mice comprise 18-20 g of 120 male mice, and are provided by Guangdong province medical experimental animal center with the qualification number SYXK (Guangdong) 2019-. The experiment is started one week after the experimental animals are adapted to the new environment, and an appropriate method is adopted to reduce the harm to the animals in the experimental process.

2. The experimental method comprises the following steps:

2.1 anti-syncytial virus infection mouse model of pneumonia

Randomly dividing mice into a blank control group, a RSV model group, a ribavirin group, a bupleurum tenue granule low dose group (5.4g/kg, which is a clinical equivalent dose of a human body), a bupleurum tenue granule medium dose group (10.8g/kg) and a bupleurum tenue granule high dose group (21.6g/kg), wherein the total number of the groups is six, 10 mice are per group, the mice are slightly anesthetized by ether, and except the blank control group, each mouse uses 25 mu L50L D₅₀The virus drops are used for nasal infection, and the blank control group is used for nasal dropping with the same amount of physiological saline. 1h after infection, performing equal volume of normal saline intragastric administration on the blank control group and the model group, and performing intragastric administration on the granule liquid medicine of bupleuri radix in the low, medium and high dosage groups of the granule of bupleuri radix, every timeOnce daily for 5 consecutive days.

2.2 ADV3 Virus-infected mouse model of pneumonia

Randomly dividing mice into a blank control group, an ADV3 model group, a ribavirin group, a small bupleurum particle low dose group (5.4g/kg, which is a clinical equivalent dose of a human body), a small bupleurum particle medium dose group (10.8g/kg) and a small bupleurum particle high dose group (21.6g/kg), wherein six groups are provided, 10 mice are in each group, and each mouse is slightly anesthetized by ether, except the blank control group, the dose of 25 mu L50L D is applied to each mouse₅₀Dripping virus into nose for infection, dripping equivalent physiological saline into nose for the blank control group 1h after infection, performing intragastric administration on the blank control group and the model group by the same volume of physiological saline, administering medical liquid of small radix bupleuri particles for administration once a day and continuously for 5 days after infection, taking blood from eyeballs of mice 6 days after infection, centrifuging at 4 ℃, 3500r/min for 15min to separate serum, storing at 20 ℃ for later use, and detecting the contents of TNF-a, ROS and I L-6 in the serum and superoxide anion (O) according to the instruction of the kit₂-) vitality units; taking out the whole lung after killing the animal, placing the lung in a homogenizer, adding normal saline, grinding to prepare homogenate, centrifuging for 20min at the temperature of 4 ℃ at 2500r/min, taking supernatant, and storing at the temperature of minus 20 ℃ for later use. Detecting the contents of CAT, SOD, GSH-px, MDA, NO and MPO in lung tissues according to the kit specification. The experimental data were statistically analyzed using SPSS 22.0 software, the data were expressed as mean. + -. standard deviation, the differences between groups were analyzed using one-way variance analysis, p<A difference of 0.05 is statistically significant.

3. The experimental results are as follows:

as shown in tables 3 (figure 1-figure 4), table 4 (figure 5-figure 10), table 5 (figure 11-figure 14) and table 6 (figure 15-figure 20), the small bupleurum particle administration is obviously changed in lung tissue, and compared with the model group, the biochemical indexes of MDA, NO, MPO, TNF-a, I L-6 and ROS contents are reduced and different, so that the small bupleurum particle administration is obviously changed in lung tissue of mice, and MDA, NO, MPO, TNF-a, I L-6 and ROS contents are differentAll have statistical significance (P is less than 0.01, P is less than 0.05), which indicates that the bupleurum tenue particles can obviously inhibit the release of oxygen free radicals in vivo, reduce the degree of lipid peroxidation and reduce the levels of various inflammatory factors, thereby reducing inflammatory reaction. The higher the unit of activity of the superoxide anion, the more superoxide anion (O) is eliminated₂-) the stronger the ability; CAT, SOD and GSH-px are important antioxidant enzymes of the organism, can clear free radicals and relieve oxidative damage. As shown in tables 3, 4, 5 and 6, the administration of bupleurum tenue granules and the comparison of the model group shows that the activities of CAT, SOD and GSH-px are increased with the anti-superoxide anion, the ability of scavenging free radicals is enhanced, the damage of lung tissues is reduced, the organism is protected, and the difference has statistical significance (P is less than 0.01, and P is less than 0.05). The results show that the bupleurum tenue particles can be used for eliminating excessive free radicals caused by RSV and ADV3 infection.

TABLE 3 Effect of bupleurum tenue particles on serum TNF-a, I L-6, ROS, anti-superoxide anion in mouse model pneumonia infected with RSV (n ═ 10)

Note: compared with the blank control group, # P <0.05, # P < 0.01; p <0.05, P <0.01, compared to model control group

TABLE 4 Effect of Xiaochaihu granules on lung tissues CAT, SOD, GSH-px, MDA, NO, MPO of mouse model pneumonia infected with RSV (n ═ 10)

TABLE 5 Effect of bupleurum tenue particles on ADV 3-infected mouse model pneumonia serum TNF-a, I L-6, ROS, anti-superoxide anion (n ═ 10)

TABLE 6 Effect of Xiaochaihu granules on lung tissues CAT, SOD, GSH-px, MDA, NO and MPO of ADV 3-infected mouse model pneumonia (n ═ 10)

4. And (4) experimental conclusion:

the bupleurum tenue particles can effectively relieve respiratory tract and lung peroxidation injury caused by syncytial virus and adenovirus in the inhibition of the syncytial virus and adenovirus and free radical injury caused by the syncytial virus and the adenovirus, increase the capability of an organism in removing free radicals and achieve the effect of treating pneumonia caused by virus infection.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed but not to be construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims

1. The application of a traditional Chinese medicine composition in preparing a medicine for preventing and treating diseases caused by respiratory virus infection is characterized in that the traditional Chinese medicine composition comprises the following active components in parts by weight: 150 +/-5 parts of radix bupleuri, 56 +/-5 parts of scutellaria baicalensis, 56 +/-3 parts of ginger processed pinellia, 56 +/-3 parts of codonopsis pilosula, 56 +/-3 parts of ginger, 56 +/-3 parts of liquorice and 56 +/-3 parts of Chinese dates, wherein the respiratory viruses are adenoviruses and/or syncytial viruses.

2. The use according to claim 1, wherein the respiratory virus is a syncytial virus and an adenovirus.

3. The use according to claim 1, wherein the respiratory virus is an adenovirus.

4. The use according to claim 3, wherein the adenovirus is ADV3 type.

5. The use according to any one of claims 1 to 4, wherein the disease is pneumonia.

6. The use of any one of claims 1 to 4, wherein the active ingredients of the Chinese medicinal composition comprise, in parts by weight: 150 parts of radix bupleuri, 56 parts of scutellaria baicalensis, 56 parts of ginger processed pinellia, 56 parts of codonopsis pilosula, 56 parts of ginger, 56 parts of liquorice and 56 parts of Chinese dates.

7. The use of claim 1, wherein the dosage form of the Chinese medicinal composition is granules.

8. The application of a traditional Chinese medicine composition in preparing a medicine for eliminating excessive free radicals caused by respiratory virus infection comprises the following active ingredients in parts by weight: 150 +/-5 parts of radix bupleuri, 56 +/-5 parts of scutellaria baicalensis, 56 +/-3 parts of ginger processed pinellia, 56 +/-3 parts of codonopsis pilosula, 56 +/-3 parts of ginger, 56 +/-3 parts of liquorice and 56 +/-3 parts of Chinese dates, wherein the respiratory viruses are syncytial viruses and/or adenoviruses.

9. The use according to claim 8, wherein the respiratory virus is a syncytial virus and an adenovirus.

10. The use of claim 8, wherein the Chinese medicinal composition is XIAOCHAIHU granule.